Kovid 19 Haberleri


        
 
Haber:
Etiketler:
Yazarın adı:
Yazarın soyadı:


27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021
ACIP reviewed information on COVID-19 vaccines and concluded that benefits of vaccination outweigh the risks of rare, serious adverse events.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=425616

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021
This report describes COVID-19 outbreaks associated with large public gatherings in Massachusetts.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=425231

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021
This report describes COVID-19 vaccine safety among U.S. adolescents aged 12-17 years.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=425230

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021
As of April 30, 2021, approximately 101 million people in the U.S. had been fully vaccinated against COVID-19. Almost 10,300 COVID-19 vaccine breakthrough infections were reported from 46 states and territories. Vaccine breakthrough infections occur in only a small fraction of all vaccinated people.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422857

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021
This report describes the circulation of influenza and other respiratory viruses during the COVID-19 pandemic.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=424882

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents - United States, April 15-23, 2021
This report describes adolescent COVID-19 vaccination acceptance and the factors that would increase adolescent vaccination, including information about COVID-19 vaccine safety and effectiveness in teenagers.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=424341

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021
This report describes a COVID-19 B.1.617.2 (Delta) variant outbreak in a gymnastics facility.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=424342

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021
In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422060

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021
The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna COVID-19 vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=422061

27 Nisan 2022, Çarşamba, 00:06 Haber Kaynağı: Çeşitli Haber Siteleri
Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021
On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421658